Dimethyltryptamine molecule:

Image from PubChem

DMT Clinical Trials


A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in patients with treatment-resistant depression


To see complete record on www.clinicaltrialsregister.eu, please visit this link

Id: 2022-000574-26

Organisation Name: GH Research Ireland Limited

Start Date: 2022-11-25

Completion Date: Ongoing

Brief Summary: Primary efficacy objective:

Country: Ireland



Total execution time in seconds: 0.091184854507446